INHIBIKASE THERAPEUTICS INC (IKT) competitors & alternatives
Health Care · NASDAQ
INHIBIKASE THERAPEUTICS INC (IKT)'s top competitors and alternatives — its most similar public companies — include Gilead Sciences (GILD), United Therapeutics (UTHR), PRELUDE THERAPEUTICS INC (PRLD), ACHIEVE LIFE SCIENCES INC (ACHV), ASSEMBLY BIOSCIENCES INC (ASMB), AVALO THERAPEUTICS INC (AVTX), RECURSION PHARMACEUTICALS INC CLAS (RXRX), KAILERA THERAPEUTICS INC (KLRA), ENLIVEN THERAPEUTICS INC (ELVN), COGENT BIOSCIENCES INC (COGT), Viatris (VTRS) and TENAX THERAPEUTICS INC (TENX). These are INHIBIKASE THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top IKT competitors & alternatives
-
Gilead SciencesGILDHealth Care
A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis,…
$130.34 (as of 2026-07-22) · market cap $163.6B
-
United TherapeuticsUTHRHealth Care
United Therapeutics is a rare disease specialist dominating pulmonary hypertension treatment through multiple treprostinil delivery formats while pursuing…
$527.07 (as of 2026-07-22) · market cap $22.7B
-
PRELUDE THERAPEUTICS INCPRLDHealth Care
An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
$3.92 (as of 2026-07-22) · market cap $313M
-
ACHIEVE LIFE SCIENCES INCACHVHealth Care
A clinical-stage biotech developing cytisinicline for smoking cessation and nicotine dependence, preparing for commercialization after completing key clinical…
$6.31 (as of 2026-07-22) · market cap $646M
-
ASSEMBLY BIOSCIENCES INCASMBHealth Care
Assembly Biosciences develops next-generation antivirals targeting herpes and hepatitis viruses, with a portfolio advancing through clinical trials and now…
$26.04 (as of 2026-07-22) · market cap $513M
-
AVALO THERAPEUTICS INCAVTXHealth Care
Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026.
$18.15 (as of 2026-07-22) · market cap $961M
-
RECURSION PHARMACEUTICALS INC CLASRXRXHealth Care
Recursion is a clinical-stage TechBio company using an AI-native operating system and massive biological datasets to industrialize and accelerate the drug…
$2.98 (as of 2026-07-22) · market cap $1.6B
-
KAILERA THERAPEUTICS INCKLRAHealth Care
A clinical-stage biotech developing a diversified pipeline of GLP-1-based obesity management drugs, led by a dual GLP-1/GIP agonist injectable designed to…
$17.79 (as of 2026-07-22) · market cap $2.4B
-
ENLIVEN THERAPEUTICS INCELVNHealth Care
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing targeted small-molecule inhibitors, with a primary focus on its lead BCR-ABL…
$52.85 (as of 2026-07-22) · market cap $3.8B
-
COGENT BIOSCIENCES INCCOGTHealth Care
Cogent Biosciences is a clinical-stage biotechnology company developing precision protein kinase inhibitors, primarily targeting KIT mutations for the…
$39.54 (as of 2026-07-22) · market cap $6.8B
-
ViatrisVTRSHealth Care
A global pharmaceutical giant supplying over 1 billion patients annually with generics, branded medicines, and an expanding innovative pipeline across more…
$17.01 (as of 2026-07-22) · market cap $20.0B
-
TENAX THERAPEUTICS INCTENXHealth Care
A Phase 3 development-stage pharmaceutical company developing novel cardiopulmonary therapies, primarily levosimendan for pulmonary hypertension and imatinib…
$14.79 (as of 2026-07-22) · market cap $418M
Not quite? Describe exactly what you want →
Peers are INHIBIKASE THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: INHIBIKASE THERAPEUTICS INC (IKT).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.